Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
blisibimod (A-623) (formerly AMG 623)
print preview
bookmark
share with colleague
General Information
Company
Amgen Inc.
Description
Peptide fusion protein that antagonizes BLyS (BAFF)
Molecular Target
BLyS (BAFF)
Mechanism of Action
BLyS (BAFF) receptor antagonist
Latest Stage of Development
Phase III
Indication
Lupus
Partner
Anthera Pharmaceuticals Inc.
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Archive Items are loading
Set Email Alert
dummy
General Information